A1: Eileen Socher & Manfred Marschall
Computer-based antiviral drug development: targeting CDKs/vCDKs as crucial determinants of cytomegalovirus and Epstein-Barr virus infections
A2: Andrea Thoma-Kreß
Enhancing immunogenicity of Human T-cell leukaemia virus Type 1 (HTLV-1) by interfering with viral transcription
A3: Thomas Gramberg
Enhancing antiviral immunity by blocking SAMHD1 and targeting viral immune evasion
A5: Jutta Eichler & Heinrich Sticht
Bispecific antiviral peptides
B2: Diana Dudziak & Christian H.K. Lehmann
Trained immunity of mononuclear phagocytes during viral infection and immunisation
B3: Christiane Krystelle Nganou-Makamdop & Thomas Harrer
Immune modulators of inflammation and exhaustion pathways as strategy to prevent immune evasion and anergy in HIV-1 infection
B5: Matthias Tenbusch
Induction of tissue-resident memory T cells by gene-based vaccines as first line of defence against pathogens entering the host via mucosal surfaces
B6: Armin Ensser
An animal model of HLA-independent, chimeric antigen receptor-mediated adoptive immunotherapy against cytomegaloviruses
B8: Kilian Schober
Ex vivo metabolic profiling of human antigen-specific T cell responses after yellow fever and SARS-CoV-2 mRNA vaccination
B9: Dennis Lapuente
A novel vaccine platform for the induction of mucosal immunity against SARS-CoV-2
C3: Marco Thomas
Protection from cytomegalovirus infection by antibodies
C4: Frank Neipel
scBCR-seq and recombinant MHV-68 for KSHV vaccine development
C5: Klaus Überla & Fulvia Ferrazzi
Improving mucosal immunity by intrastructural help
C6: Bettina Hohberger
Functionally active autoantibodies targeting G-protein-coupled receptors in patients with Long-/Post-COVID
C7: Anja Lux
Therapeutic efficacy of SARS-CoV-2 specific IgG with enhanced Fc receptor functions
C8: Vladimir Temchura
Antiviral memory T follicular cells as a correlate of vaccination efficacy
